Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology and
2 other channels

Expert Opinion / Interview · June 18, 2019

Clinical Implications of New Data on Apalutamide + ADT in Castrate-Sensitive Prostate Cancer

Sumanta Pal MD
Neeraj Agarwal MD
Interview with
Neeraj Agarwal MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Neeraj Agarwal MD

Sumanta Pal MD

Further Reading

Related Videos